The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is a huge mover today! About 242,650 shares traded hands. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has risen 41.14% since April 25, 2016 and is uptrending. It has outperformed by 35.13% the S&P500.
The move comes after 5 months positive chart setup for the $777.42M company. It was reported on Nov, 28 by Barchart.com. We have $17.98 PT which if reached, will make NASDAQ:SCMP worth $54.42M more.
Analysts await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings on March, 14. They expect $0.44 EPS, 0.00% or $0.00 from last year’s $0.44 per share. SCMP’s profit will be $20.36M for 9.55 P/E if the $0.44 EPS becomes a reality. After $0.28 actual EPS reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 57.14% EPS growth.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage
Out of 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Sucampo Pharma has been the topic of 21 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Friday, November 13 by Mizuho. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Hold” rating given on Wednesday, March 9 by Jefferies. The stock has “Mkt Perform” rating given by Leerink Swann on Thursday, September 3. Mizuho upgraded the shares of SCMP in a report on Wednesday, April 20 to “Buy” rating. The rating was maintained by Maxim Group with “Buy” on Wednesday, August 26. Mizuho maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Monday, November 14 with “Neutral” rating. The firm has “Buy” rating by H.C. Wainwright given on Monday, August 24. The rating was initiated by Mizuho with “Neutral” on Friday, October 9. The firm has “Buy” rating given on Tuesday, February 9 by UBS. The company was maintained on Thursday, August 27 by WallachBeth Capital.
According to Zacks Investment Research, “Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.”
Insitutional Activity: The institutional sentiment is 0.98 in Q2 2016. Its the same as in 2016Q1. The ratio is flat, as 17 funds sold all Sucampo Pharmaceuticals, Inc. shares owned while 46 reduced positions. only 22 funds bought stakes while 40 increased positions. They now own 17.83 million shares or 12.41% less from 20.36 million shares in 2016Q1.
Blackrock Limited Liability Company has 132,982 shares for 0% of their US portfolio. Springbok Ltd Liability Corporation accumulated 11,961 shares or 0.02% of the stock. Blackrock Invest Mngmt Ltd holds 0% or 92,447 shares in its portfolio. Deutsche Fincl Bank Ag accumulated 31,492 shares or 0% of the stock. Bnp Paribas Arbitrage Sa owns 1,044 shares or 0% of their US portfolio. American holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 13,484 shares. Great West Life Assurance Com Can accumulated 3,575 shares or 0% of the stock. Amer Century Incorporated last reported 0% of its portfolio in the stock. Moreover, Commercial Bank Of Montreal Can has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 25,285 shares. The New York-based Cornerstone Cap Ltd Co has invested 0.01% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Moreover, Barclays Public Ltd Company has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 600 shares. Moreover, Numeric Investors Ltd Company has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 40,800 shares. Sg Americas Ltd Co last reported 40,316 shares in the company. Blackrock Institutional Tru Co Na owns 653,762 shares or 0% of their US portfolio. Alliancebernstein Limited Partnership has invested 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).
Insider Transactions: Since November 15, 2016, the stock had 0 insider buys, and 1 insider sale for $27,514 net activity. $27,514 worth of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) shares were sold by Smith Andrew P.
More recent Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) news were published by: Marketwatch.com which released: “Sucampo Pharmaceuticals Inc. Cl A” on February 06, 2011. Also Bizjournals.com published the news titled: “Sucampo acquires exclusive option for cancer drug in deal worth up to $190 million” on January 11, 2016. Moodys.com‘s news article titled: “Moody’s assigns B3 CFR to Sucampo Pharmaceuticals” with publication date: October 01, 2015 was also an interesting one.
SCMP Company Profile
Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a biopharmaceutical company. The Firm focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology inflammatory disorders. The Firm operates through development and commercialization of pharmaceutical products segment. The Company’s activities are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts activities in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.